Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 5/20 | 0.36 |
| ▸ | DPP8 | Q6V1X1 | 4/20 | 0.32 |
| ▸ | DPP9 | Q86TI2 | 4/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | CAPN1 | P07384 | 2/20 | 0.30 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.30 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.30 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.30 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23734370 | 0.86 | ABCG2 (0.32) | — | |
| SCHEMBL23734389 | 0.79 | HINT1 (0.36) | F2 | |
| SCHEMBL23734257 | 0.79 | F2 (0.41) | F2PRSS1PRSS2PRSS3TPSAB1 | |
| SCHEMBL23734501 | 0.79 | F2 (0.41) | F2PRSS1PRSS2PRSS3TPSAB1 | |
| SCHEMBL23734383 | 0.79 | F2 (0.38) | F2PRSS1PRSS2PRSS3TPSAB1 | |
| SCHEMBL21786921 | 0.75 | F2 (0.48) | F2 | |
| SCHEMBL21787064 | 0.75 | F2 (0.48) | F2 | |
| SCHEMBL23734371 | 0.74 | — | — | |
| SCHEMBL23734238 | 0.73 | RNASE1 (0.37) | — | |
| SCHEMBL23734232 | 0.72 | TOP2A (0.37) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11085076-B2 | Synthesis of novel disulfide linker based nucleotides as reversible terminators for DNA sequencing by synthesis | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2021-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11085076-B2 | Synthesis of novel disulfide linker based nucleotides as reversible terminators for DNA sequencing by synthesis | POLRMT, RNGTT, MTR | F2 2899/4885DPP8 3112/4885DPP9 4161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.